Certain Restricted Stock Units of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023.
July 22, 2023
Share
Certain Restricted Stock Units of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023. These Restricted Stock Units will be under lockup for 46 days starting from 7-JUN-2023 to 23-JUL-2023.
Details:
The company's officers and directors have agreed, subject to certain specified exceptions, not to directly or indirectly sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open ?put equivalent position? within the meaning of Rule 16a-l(h) under the Exchange Act, or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, for a period of 45 days after the date of the underwriting agreement.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
VAXART, INC. 
